Global Subdermal Contraceptive Implants Market Size, Trend & Opportunity Analysis Report, by Product (Etonogestrel Implant, Levonorgestrel Implant), and Forecast, 2025-2035
Global Subdermal Contraceptive Implants Market Size, Opportunity Analysis and Forecast, 2025-2035
Market Definition and Introduction
The Global Subdermal Contraceptive Implants Market was valued at USD 1.12 billion in 2024 and is anticipated to reach USD 2.53 billion by 2035, expanding at a CAGR of 7.68% during the forecast period 2025-2035. The present subdermal contraceptive implant market represents a transformational avenue in reproductive health, with changing social attitudes towards long-acting reversible contraceptives (LARCs) paving the way. Alongside healthcare ecosystems worldwide reshaping themselves to provide safer and more convenient but effective contraceptive measures to women, the durability, user-friendliness, and nearly perfect efficacy of implants have promoted acceptance of this contraceptive method. Healthcare practitioners are also endorsing them as a useful way to avoid unintended pregnancies and improve compliance with long-acting reversible contraceptives compared to short-term methods.
Inadequate access to contraceptive solutions in low- and middle-income nations catalysed mounting awareness campaigns by governments and NGOs for this market. International health organisations promote contraceptive equity by fostering broader availability of implants under public health schemes and subsidised programs. At the same time, the acceptance of implants is slowly growing even in rural communities for family planning, just as reproductive choices of women are changing in urban centres.
In turn, pharmaceutical manufacturers have recognised this emerging trend and are now investing large amounts to develop next-generation implants with longer duration, better biocompatibility, and easier insertion. Concurrently, discussions and dialogues around reproductive rights, increased female labour force participation, and higher levels of education are all contributing to the evolution of consumer choices. With acceptance building among younger women and first-time contraceptive users alike, the subdermal implant is gradually carving out its place within the pantheon of modern contraceptive options.
Recent Developments in the Industry
- In March 2024, saw Merck & Co. establish strategic alliances with health ministries across Southeast Asia and Sub-Saharan Africa to increase the reach of its principal product Implanon NXT. This initiative seeks to enhance the availability of implants in underserved areas still facing high levels of unmet contraceptive needs through public-private partnerships. By using government distribution channels and local NGOs, Merck is enhancing its foothold while fulfilling global commitments to reproductive health equity.
- In July 2024, Bayer AG announced an R&D programme for levonorgestrel implants that are designed to go beyond five years, enhancing long-term contraceptive efficacy while minimising the need for repeat clinical visits. This innovation aims at women who want longer protection without maintenance activities. The development has already attracted the interest of regulators and family planning agencies who are keen to introduce longer-acting contraceptives into health systems.
- In February 2023, saw a landmark achievement by Shanghai Dahua Pharmaceutical Co., Ltd. in obtaining WHO prequalification for its levonorgestrel implant, immensely placing the company in the cadre of compressed large-scale procurement programmes supported by the UNFPA and other international donors. This act significantly enables global supply chains that have, up until now, relied on limited suppliers, thus making it more affordable for low-income people.
Market Dynamics
Rising demand for long-acting contraceptives propels the highest adoption of subdermal implants across the world.
Steadily growing demand for long-acting reversible contraceptives (LARCs) has become a defining driver in the subdermal implants market. Women across diverse demographics are relating themselves towards implants due to low maintenance, an efficacy rate of >99%, and long-term protection for several years. The burden of unintended pregnancies has put severe strain on health care resources, and thus the delay on the part of policymakers and organisations to actively promote LARCs will be a more Cost-Effective and sustainable alternative solution. The exceptionally proactive development was bolstered by very strong educational outreach campaigns and continues to drive market penetration, especially in countries where demand is generally low historically.
Cultural barriers and misconceptions restrain adoption across conservative societies.
Adoption across certain countries remains constrained despite strong growth, mainly because of socio-cultural barriers, myths, and misconceptions surrounding contraceptive implants. Resistance usually stems from the absence of knowledge or misconceptions about side effects and restoration of fertility. The existence of religious objections in some parts of Africa, the Middle East, and South Asia adds a layer of resistance that slows the overall momentum of the market. Culturally appropriate awareness campaigns and positive engagement of community health workers, who can counter misinformation at the grassroots level, are critical in addressing these barriers.
Regulatory hurdles and cost constraints pose a challenge for manufacturers and healthcare systems.
In spite of praises for efficiency, the subdermal implant manufacturers have found it hard to wade through the regulatory quagmire or get sensible price earnings. An extraordinarily high price usually turns away women who see themselves in the developing regions of the world; they are ready to accept subsidised versions, which are sometimes not available. Simultaneously, manufacturers are heavily investing in regulatory compliance for approval in different jurisdictions, which inevitably hampers the timely rollout and inflates their operational costs. Supply chain constraints amplify some of these challenges, which therefore work against the widespread uptake of these implants.
Innovative implant design and increased government funding will provide new growth opportunities.
The ongoing innovation pipeline in implant technology-from biodegradable materials to techniques for easier insertion a promising pathway for market expansion. With international agencies and governments increasingly directing funds toward women's health initiatives with the goal of overall access to contraceptive implants is being widened. The powerful design of a public-private partnership is expected to lead to great affordability and accessibility, bringing in enormous growth prospects within underserved areas. In the long term, the population will aggressively enter the mainstream of universal administration systems, thereby going on to grow exponentially in any market scenario.
Attractive Opportunities in the Market
- Next-Gen Implants - Extended-duration implants with biodegradable materials present promising innovation for longer efficacy and comfort.
- Government Programmes Expansion - Public health funding in low-income nations expands equitable access to affordable contraceptive implants.
- NGO Partnerships - Collaborations with NGOs strengthen grassroots campaigns to reduce cultural barriers and improve acceptance.
- Emerging Market Surge - Rapid adoption in Asia-Pacific and Africa driven by high fertility rates and unmet contraceptive demand.
- Regulatory Approvals - WHO prequalification and FDA approvals enhance global trust and widen procurement opportunities.
- Digital Awareness Tools - Mobile health applications improve knowledge dissemination and aid informed contraceptive choices for women.
- Pharma Collaborations - Strategic alliances enhance R&D and production capacity for next-generation subdermal implants.
- Supply Chain Expansion - Regional manufacturing hubs reduce dependence on limited suppliers and stabilise global availability.
- Eco-Friendly Materials - Development of biodegradable implants aligns with sustainability-focused healthcare initiatives.
- Healthcare Workforce Training - Training clinicians in insertion techniques ensures higher adoption and minimises procedural risks.
Report Segmentation
By Product: Etonogestrel Implant, Levonorgestrel Implant
By End Use: Hospitals, Gynaecology Clinics, Family Planning Centres, Community Health Centres
By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)
Key Market Players: Merck & Co., Bayer AG, Shanghai Dahua Pharmaceutical Co., Ltd., Anhui Zhongxing Pharmaceutical Co., Ltd., Shanghai Hualian Pharmaceutical Co., Ltd., Gedeon Richter Plc., DKT International, Mylan N.V., Allergan plc, and Cipla Limited.
Report Aspects
Base Year: 2024
Historic Years: 2022, 2023, 2024
Forecast Period: 2024-2035
Report Pages: 296
Dominating Segments
In market share, etonogestrel implants rule the roost, backed by effective efficacy rates and worldwide acceptance in family planning.
There seems to be no child's play along with the proper clinical evidence, with a good storage of research data. And this is an exception to these implantations (Implanon NXT by Merck & Co) of etonogestrel, enjoying wider acceptance among the people as far as subdermals cater to family planning worldwide. The contraceptive implant provides three years of continuous contraception, prompting women all the more for the trouble-free method, minus the need for daily or monthly compliance. Besides, health professionals love it because data are more cemented on the sound safety profile, the rehabilitation of fertility soon after removal being one. Other global health-related agencies of the
WHO and UNFPA support etonogestrel implant in bulk to distribute in the developing world. Well-documented cost-effectiveness in healthcare economics, besides efficacious considerations, is also perceived as a long-term solution for public healthcare programs to control the high abortion rates in the face of unintended pregnancies.
Levonorgestrel implants emerge from a socioeconomic platform wherein they are being employed in subsidised programs championed by
donor interest.
Levonorgestrel implants, such as Jadelle and Sino-implant (II), scurrying across a landscape, are gaining market share in large donor-funded projects due to their low cost and largely unavailable availability in developing countries. The weight of these grades of implants under five years of action lends to their attractiveness in poorly rated healthcare systems with a rigid anti-chronic basis of stereotypical visits. WHO's prequalification of products like Shanghai Dahua's levonorgestrel implant has rendered them not only procured but also proliferated through donor funds. For levonorgestrel implants, stepping into high gear, as essential as they are to plans of family welfare, is quite a matter different to etonogestrel implants. Pregnant with poverty, Levonorgestrel, by its cost-effectivity and its sheer provision of contraceptive fertility rights without the fear of pregnancy, gives both psychological comfort and trust in the minds of the user. For the last ten years and following, it seems likely that levonorgestrel implanting will grow ever stronger across Africa and Asia, with the momentum being bolstered by both governments and private companies aiming for win-win target goals.
Leveraging the professional healthcare systems, hospitals will occupy the front of the end-use segment.
Whereas hospitals are the marker of the entire sector gathered into end-use, this very access comes with medical infrastructure with trained healthcare personnel to handle almost every part of the technology. Implants require induction and removal by a professional, and this quality makes hospitals the most reliable point of care for those clients who need to go into contraceptive mode vis---vis any of these. Parked mainly at the portals of state expenditure, particularly public hospitals, government-aided family planning programs run from here, providing certain access to a vast class of the public to family planning. On the other side of the coin, private hospitals provide services to private-partnered urban and semi-urban women, who may perhaps need limited interference from the public in this sector. The increasing procurement of the health rights of women and public and private partnerships in permitting healthcare service delivery have propelled hospitals to retain their frontline function concerning implant uptake.
Key Takeaways
- Etonogestrel Dominance - Etonogestrel implants lead due to clinical efficacy, strong NGO backing, and wide acceptance in healthcare systems.
- Levonorgestrel Momentum - Affordable levonorgestrel implants accelerate adoption in donor-funded initiatives across Africa and Asia.
- Hospital Leadership - Hospitals dominate as primary points of insertion due to infrastructure and availability of trained clinicians.
- Clinic Expansion - Gynaecology clinics and family planning centres expand access through community outreach and personalised care.
- Global Equity Drive - NGO and government-led initiatives bridge contraceptive access gaps in underserved populations.
- Innovation Pipeline - Next-generation implants focus on extended efficacy, simplified insertion, and biodegradable materials.
- Cultural Resistance - Persistent misconceptions and religious barriers continue to slow adoption in conservative societies.
- Supply Chain Strengthening - WHO prequalification and regional manufacturing hubs diversify supply and reduce procurement risks.
- Policy Backing - Supportive government funding and health system integration amplify adoption and affordability worldwide.
- Emerging Market Surge - Rapid adoption in Asia-Pacific and Africa propels growth, driven by high fertility rates and unmet needs.
Regional Insights
North America leads the market with a robust healthcare infrastructure, favourable reimbursement, and rising LARC preference.
North America, particularly the United States, dominates the subdermal contraceptive implants market owing to its advanced healthcare systems, strong policy support, and high levels of contraceptive awareness. The region has witnessed a significant shift towards long-acting reversible contraceptives, largely driven by insurance coverage under the Affordable Care Act and increasing support from healthcare providers promoting implants as safe and cost-efficient. The presence of major market players, coupled with ongoing research in next-generation implants, ensures that innovation remains at the forefront. Furthermore, the growing participation of younger women in workforce activities, coupled with lifestyle choices prioritising convenience, continues to drive adoption. Canada and Mexico also reflect rising uptake,
supported by government-led public health programmes integrating implants into broader contraceptive portfolios.
Europe maintains leadership in innovation and reproductive healthcare policies supporting the wide adoption of implants.
Europe remains at the forefront of advancing reproductive health owing to progressive healthcare policies, widespread contraceptive
awareness, and a strong emphasis on gender equality. Countries such as the UK, France, and the Netherlands lead adoption, benefiting from universal healthcare systems that cover implant insertion under national health services. The European Medicines Agency-s stringent regulatory standards have encouraged manufacturers to innovate while ensuring patient safety, particularly with extended-duration implants. Moreover, cultural acceptance of contraceptives is significantly higher in Europe compared to other regions, reducing barriers to adoption. With governments continuing to integrate implants into nationwide family planning strategies, the region is expected to maintain steady growth throughout the forecast period, consolidating its position as a hub for innovation and regulatory leadership.
Asia-Pacific is the fastest-growing market, propelled by unmet contraceptive needs and government-backed initiatives.
Asia-Pacific is projected to witness the most accelerated growth in subdermal contraceptive implants, underpinned by large populations, high fertility rates, and substantial unmet contraceptive demand. Governments in China, India, and Indonesia are increasingly prioritising reproductive health through subsidies, awareness campaigns, and collaborations with global NGOs. Pharmaceutical manufacturers based in China have also gained traction in producing affordable levonorgestrel implants, enabling large-scale supply for both domestic and international markets. As urbanisation and female education levels rise, women are making more informed reproductive health choices, accelerating adoption in both urban and rural areas. With improving healthcare infrastructure and the presence of cost-effective local players, the Asia-Pacific region is poised to become the central growth engine for the global market over the coming decade.
The LAMEA market grows steadily with donor-driven initiatives addressing contraceptive access challenges in underserved regions.
Latin America, the Middle East, and Africa (LAMEA) are witnessing steady growth in implant adoption, primarily driven by international donor programmes and public health initiatives aimed at reducing unintended pregnancies. In Africa, where unmet contraceptive needs remain particularly high, global health organisations such as UNFPA and USAID play a pivotal role in distributing subsidised implants to women in rural communities. Latin America shows rising demand as governments integrate implants into broader reproductive health policies, while Middle Eastern adoption faces cultural and religious resistance. Nevertheless, targeted awareness campaigns and healthcare workforce training are gradually breaking down these barriers. As donor funding and government-led initiatives continue to expand, LAMEA is set to emerge as an increasingly influential player in the global subdermal implants landscape.
Key Benefits for Stakeholders
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.
Frequently Asked Question(FAQ) :
Etonogestrel implants currently hold the leading market share. Their dominance is attributed to high clinical efficacy (over 99%), strong backing from NGOs, and wide acceptance within healthcare systems, particularly Merck & Co.’s Implanon NXT, which is favored for its three-year continuous protection and rapid restoration of fertility after removal.
Adoption is driven by the low maintenance requirements of implants, their near-perfect efficacy rate, and their cost-effectiveness as a long-term solution to prevent unintended pregnancies. Additionally, educational outreach campaigns and the shift in consumer preference toward convenient, "set-and-forget" reproductive health options are significant factors.
Asia-Pacific is projected to be the fastest-growing region. This growth is fueled by large populations, high fertility rates, and significant unmet contraceptive needs. Growth is further accelerated by government subsidies in countries like China, India, and Indonesia, alongside the emergence of affordable local manufacturers.
Hospitals represent the leading end-use segment because the insertion and removal of subdermal implants require specialized medical infrastructure and trained healthcare professionals. They serve as the primary points of care for both government-aided public health programs and private healthcare services.
In several conservative societies across Africa, the Middle East, and South Asia, adoption is hindered by myths, misconceptions regarding side effects, religious objections, and a lack of knowledge about the restoration of fertility. Addressing these requires culturally appropriate awareness campaigns and grassroots engagement.
In July 2024, Bayer AG announced an R&D program for levonorgestrel implants designed to last beyond five years. Such innovations aim to enhance long-term efficacy and reduce the frequency of clinical visits, catering to women seeking extended protection without the need for regular maintenance.
WHO prequalification, recently achieved by Shanghai Dahua Pharmaceutical Co., Ltd. for its levonorgestrel implant, is a landmark achievement. it allows companies to participate in large-scale procurement programs supported by international donors like the UNFPA, thereby stabilizing global supply chains and making implants more affordable in low-income regions.
The market features prominent pharmaceutical and healthcare companies, including Merck & Co., Bayer AG, Shanghai Dahua Pharmaceutical Co., Ltd., Anhui Zhongxing Pharmaceutical Co., Ltd., Gedeon Richter Plc., DKT International, and Cipla Limited.
Significant opportunities lie in the development of "Next-Gen Implants," which include the use of biodegradable materials that eliminate the need for surgical removal. Other opportunities include the expansion of public-private partnerships to improve accessibility in underserved areas and the use of digital health tools to improve contraceptive awareness.
